Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Diffuse cirrhosis-like hepatocellular carcinoma: a clinically and radiographically undetected variant mimicking cirrhosis.

Jakate S, Yabes A, Giusto D, Naini B, Lassman C, Yeh MM, Ferrell LD.

Am J Surg Pathol. 2010 Jul;34(7):935-41. doi: 10.1097/PAS.0b013e3181ddf52f.

PMID:
20463569
2.

Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis.

Snowberger N, Chinnakotla S, Lepe RM, Peattie J, Goldstein R, Klintmalm GB, Davis GL.

Aliment Pharmacol Ther. 2007 Nov 1;26(9):1187-94.

3.

Alpha-fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies.

Murugavel KG, Mathews S, Jayanthi V, Shankar EM, Hari R, Surendran R, Vengatesan A, Raghuram K, Rajasambandam P, Murali A, Srinivas U, Palaniswamy KR, Pugazhendhi T, Thyagarajan SP.

Int J Infect Dis. 2008 Nov;12(6):e71-6. doi: 10.1016/j.ijid.2008.04.010. Epub 2008 Jul 26.

4.

Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver.

Cho HJ, Kim B, Lee JD, Kang DR, Kim JK, Lee JH, Shin SJ, Lee KM, Yoo BM, Lee KJ, Kim SS, Cheong JY, Cho SW.

Am J Gastroenterol. 2017 Mar;112(3):460-470. doi: 10.1038/ajg.2016.480. Epub 2016 Oct 25.

PMID:
27779194
5.

Hepatocellular carcinoma and its early detection by AFP testing in Mongolia.

Oyunsuren T, Sanduijav R, Davaadorj D, Nansalmaa D.

Asian Pac J Cancer Prev. 2006 Jul-Sep;7(3):460-2.

6.

Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis.

Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, Chen WM, Shen CH, Lu CH, Wu CS, Tsai YH, Huang YH.

Am J Gastroenterol. 2015 Jun;110(6):836-44; quiz 845. doi: 10.1038/ajg.2015.100. Epub 2015 Apr 14.

PMID:
25869392
7.

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.

Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A, Stein K.

Health Technol Assess. 2007 Sep;11(34):1-206. Review.

8.

Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein.

Paul SB, Gulati MS, Sreenivas V, Madan K, Gupta AK, Mukhopadhyay S, Acharya SK.

Oncology. 2007;72 Suppl 1:117-23. Epub 2007 Dec 13.

PMID:
18087192
9.

Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis.

Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB.

Hepatology. 2002 Aug;36(2):410-7.

PMID:
12143050
10.

Hepatocellular carcinoma in Belgium: clinical and virological characteristics of 154 consecutive cirrhotic and non-cirrhotic patients.

Van Roey G, Fevery J, Van Steenbergen W.

Eur J Gastroenterol Hepatol. 2000 Jan;12(1):61-6.

PMID:
10656212
11.

Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis.

Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, Kandunoori P, Singal AG.

Clin Gastroenterol Hepatol. 2014 May;12(5):870-7. doi: 10.1016/j.cgh.2013.09.053. Epub 2013 Oct 2.

12.

[Hepatocellular carcinoma in Germany. Epidemiology, etiology, clinical aspects and prognosis in 100 consecutive patients of a university clinic].

Petry W, Heintges T, Hensel F, Erhardt A, Wenning M, Niederau C, Häussinger D.

Z Gastroenterol. 1997 Dec;35(12):1059-67. German.

PMID:
9487638
13.

Diagnostic sensitivity of hepatocellular carcinoma imaging and its application to non-cirrhotic patients.

Lin MT, Chen CL, Wang CC, Cheng YF, Eng HL, Wang JH, Chiu KW, Lee CM, Hu TH.

J Gastroenterol Hepatol. 2011 Apr;26(4):745-50. doi: 10.1111/j.1440-1746.2010.06501.x.

PMID:
21418303
14.
15.

Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.

Liu X, Chi X, Gong Q, Gao L, Niu Y, Chi X, Cheng M, Si Y, Wang M, Zhong J, Niu J, Yang W.

PLoS One. 2015 May 21;10(5):e0127518. doi: 10.1371/journal.pone.0127518. eCollection 2015.

16.

Clinical utility of alpha fetoprotein and HCCR-1, alone or in combination, in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.

Jirun P, Zhang G, Kim HK, Ha SA, Zhongtian J, Shishi Q, Zhuqingqing C, Lei G, Yoo J, Kim S, Park YG, Wang J, Yang Y, Xu Z, Huang Z, Lee YK, Song EY, Kim JW.

Dis Markers. 2011;30(6):307-15. doi: 10.3233/DMA-2011-0789.

17.

Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients.

Li B, Liu H, Shang HW, Li P, Li N, Ding HG.

Afr Health Sci. 2013 Sep;13(3):703-9. doi: 10.4314/ahs.v13i3.26.

18.

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Brú C, Bruix J.

Hepatology. 2008 Jan;47(1):97-104. Erratum in: Hepatology. 2008 Feb;47(2):769.

PMID:
18069697
19.

Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma.

Khien VV, Mao HV, Chinh TT, Ha PT, Bang MH, Lac BV, Hop TV, Tuan NA, Don LV, Taketa K, Satomura S.

Int J Biol Markers. 2001 Apr-Jun;16(2):105-11.

PMID:
11471892
20.

New perspectives and strategy research biomarkers for hepatocellular carcinoma.

Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B.

Clin Chem Lab Med. 2007;45(9):1169-79. Review.

PMID:
17635075

Supplemental Content

Support Center